# Enhanced Effectiveness of Onabotulinum Toxin A in Combination With Definisse KP1 Eye Contour Cream for Upper Face Rejuvenation: A Case Series

**Authors:** Ilaria Proietti, Martina Manni

PMC · DOI: 10.1111/jocd.70743 · Journal of Cosmetic Dermatology · 2026-03-16

## TL;DR

Combining onabotulinum toxin A injections with a specific eye cream improved upper face rejuvenation and skin quality more than using the toxin alone.

## Contribution

Demonstrates enhanced effectiveness of combining onabotulinum toxin A with a bioactive peptide cream for upper face rejuvenation.

## Key findings

- The +KP1 group showed improvement in all variables except for eye erythema and oedema.
- The Control group only improved in eye impairment severity and periocular wrinkles.
- Subjects in the +KP1 group reported higher satisfaction with the treatment protocol.

## Abstract

Among antiaging treatments, botulin toxin A injection is one of the most widely used. KP1 (Serpine A1‐III) is a recently developed bioactive peptide that increases collagen type I by enhancing its synthesis and preventing its degradation.

This case series described the combinatorial effect of onabotulinum toxin A injection with Definisse KP1 eye contour cream application in the treatment of skin aging in the upper third of the face.

Adult subjects with moderate to severe dynamic wrinkles who received onabotulinum toxin A combined with Definisse KP1 eye contour cream (Onabotulinum toxin A + KP1 group, hereinafter referred to as + KP1 group) or onabotulinum toxin A alone (Control group) were included in the analysis. The following variables were measured: severity of the disorder, skin hypersensitivity, erythema, oedema, periocular wrinkles, skin quality, hydration‐creepiness, and tightness; each parameter was evaluated in both eyes 4 weeks posttreatment.

Data from 22 in the + KP1 group and 19 in the Control group were collected. In the + KP1 group, all variables improved, except for eye erythema and eye oedema. Conversely, in the Control group, only eye impairment severity and periocular wrinkles improved from baseline. In the satisfaction questionnaire, the overall evaluation of the protocol achieved higher scores in the + KP1 group than in the Control group.

From this case series, the application of Definisse KP1 eye contour cream seems to enhance the effect of onabotulinum toxin A injection on periocular wrinkles and provide additional benefits in skin quality; the combined procedure was tolerated, feasible, and appreciated by subjects.

## Full-text entities

- **Genes:** ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, SERPINA1 (serpin family A member 1) [NCBI Gene 5265] {aka A1A, A1AT, AAT, PI, PI1, PRO2275}, ELANE (elastase, neutrophil expressed) [NCBI Gene 1991] {aka ELA2, GE, HLE, HNE, NE, PMN-E}
- **Diseases:** atrophy (MESH:D001284), skin infections (MESH:D007239), eye oedema (MESH:C536897), excessive skin laxity (MESH:D007593), Fitzpatrick skin type I (MESH:D006969), skin fragility (MESH:C536183), psoriasis (MESH:D011565), ptosis (MESH:C564553), hematomas (MESH:D006406), pain (MESH:D010146), wrinkles (MESH:D019773), myasthenia gravis (MESH:D009157), tissue damage (MESH:D017695), eye impairment (MESH:D005128), dysmorphic disorder (MESH:D057215), cutaneous disorder (MESH:D018366), erythema (MESH:D004890), neuromuscular disorders (MESH:D009468), inflammatory (MESH:D007249), allergy (MESH:D004342), skin hypersensitivity (MESH:D012871), amyotrophic lateral sclerosis (MESH:D000690), Eaton-Lambert syndrome (MESH:D015624), eczema (MESH:D004485), hypertrophy (MESH:D006984)
- **Chemicals:** EMLA (MESH:D000077442), KP1 (-), lidocaine (MESH:D008012), prilocaine (MESH:D011318), hyaluronic acid (MESH:D006820), aminoglycosides (MESH:D000617), acetylcholine (MESH:D000109), glycosaminoglycans (MESH:D006025), niacinamide (MESH:D009536), L-ascorbic acid (MESH:D001205), acetyl hexapeptide-8 (MESH:C582852)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** A1 C

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12990165/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12990165/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12990165/full.md

---
Source: https://tomesphere.com/paper/PMC12990165